Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Recursion Pharmaceuticals Inc(RXRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RXRX
10/02/2026: RXRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that distinguishes itself by using an AI-enabled platform to decode biology and accelerate drug discovery. Its primary strengths lie in its massive proprietary dataset and deep integration of machine learning with automated lab processes, supported by strategic partnerships with companies like NVIDIA. The company's growth story is centered on proving that its digital platform can successfully lead drug candidates to clinical approval. However, Recursion faces significant execution and competition risks, as the efficacy of its AI-led approach remains to be fully proven in clinical settings. This stock is best suited for growth-oriented investors with a high tolerance for risk and a long-term time horizon.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-risk, high-reward exposure to the intersection of AI and biotechnology. |
| Momentum investor | Mixed fit | Momentum depends heavily on clinical milestones and partnership news cycles. |
| Value investor | Weak fit | The company lacks current profitability and traditional valuation metrics are difficult to apply. |
| Dividend investor | Weak fit | Recursion is a reinvestment-focused company and does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and the inherent uncertainty of drug discovery make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on clinical data releases and sector sentiment. |
| Valuation risk | High | Valuations are speculative and rely on long-term projections rather than current cash flow. |
| Competition risk (AI competition) | Medium / high | The sector is crowded with well-funded competitors racing to prove AI efficacy. |
| Business quality | Medium | While the platform is robust, the company is still proving its ability to successfully commercialize drugs. |
| Dividend income | Low / none | There is no income component to this investment. |
| Execution risk | High | The complexity of merging AI discovery with clinical development presents significant execution challenges. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -64.78% | Avg. Invested days 12 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.18B USD | Price to earnings Ratio - | 1Y Target Price 7.22 |
Price to earnings Ratio - | 1Y Target Price 7.22 | ||
Volume (30-day avg) 19.2M shares | Beta 1.07 | 52 Weeks Range 2.77 - 7.18 | Updated Date 10/02/2026 |
52 Weeks Range 2.77 - 7.18 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Partnership Collaborations | Upfront payments, R&D funding, and potential milestone payments from partners. | Revenue is largely driven by large pharma partners paying to use the Recursion OS. |
| Internal Pipeline | Proprietary drug programs that may lead to future licensing or commercial products. | This is the 'long-term bet' where successes in the pipeline could lead to future growth. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.52B | Price to Sales(TTM) 39.79 |
Enterprise Value 1.52B | Price to Sales(TTM) 39.79 | ||
Enterprise Value to Revenue 28.26 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 535.34M | Shares Floating 518.47M |
Shares Outstanding 535.34M | Shares Floating 518.47M | ||
Percent Insiders 2.04 | Percent Institutions 70.65 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Recursion Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Salt Lake City, UT, United States | ||
IPO Launch date 2021-04-16 | CEO, President & Director Dr. Najat Khan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 600 | Website https://www.recursion.com |
Full time employees 600 | Website https://www.recursion.com | ||
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.